AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
All that glitters is not gold.
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
Shoppers are being hit by double whammy of oil and rising rates.
stocks
ASX data center player sells US assets to bolster balance sheet
Asset sale in response to growing investor concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,089.40 | 19.30 | 0.21% |
| CAC 40 | 8,299.42 | 237.11 | 2.94% |
| DAX 40 | 24,918.69 | 516.99 | 2.12% |
| Dow JONES (US) | 49,910.59 | 612.34 | 1.24% |
| FTSE 100 | 10,438.66 | 219.55 | 2.15% |
| HKSE | 26,623.94 | 410.16 | 1.56% |
| NASDAQ | 25,838.94 | 512.82 | 2.02% |
| Nikkei 225 | 62,816.95 | 3,303.83 | 5.55% |
| NZX 50 Index | 13,244.37 | 99.18 | 0.75% |
| S&P 500 | 7,365.12 | 105.90 | 1.46% |
| S&P/ASX 200 | 8,862.80 | 17.40 | 0.20% |
| SSE Composite Index | 4,170.75 | 10.57 | 0.25% |